Literature DB >> 19541274

Repeat probing for treatment of persistent nasolacrimal duct obstruction.

Michael X Repka, Danielle L Chandler, Don L Bremer, Mary Louise Z Collins, Dave H Lee.   

Abstract

Repeat probing of the nasolacrimal duct is one treatment option for children with persistent symptoms of nasolacrimal duct obstruction (NLDO) following an initial probing. The authors conducted a prospective, multicenter study in which 20 subjects age 6 to <48 months underwent a repeat probing for symptomatic NLDO and had follow-up visits 1 month and 6 months after surgery. Treatment success was defined as the absence of all three clinical signs of nasolacrimal duct obstruction-epiphora, increased tear lake, and mucous discharge. Repeat probing was successful in 56%(95% CI, 33%-76%) of cases.

Entities:  

Mesh:

Year:  2009        PMID: 19541274      PMCID: PMC2795353          DOI: 10.1016/j.jaapos.2009.02.008

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  6 in total

1.  The failed probing.

Authors:  B A O'Donnell; J P Adenis; J V Linberg; G E Rose; T J Sullivan; J L Wobig
Journal:  Clin Exp Ophthalmol       Date:  2001-10       Impact factor: 4.207

2.  Office probing of congenital nasolacrimal duct obstruction.

Authors:  D Stager; J D Baker; T Frey; D R Weakley; E E Birch
Journal:  Ophthalmic Surg       Date:  1992-07

3.  Models for longitudinal data: a generalized estimating equation approach.

Authors:  S L Zeger; K Y Liang; P S Albert
Journal:  Biometrics       Date:  1988-12       Impact factor: 2.571

4.  Primary treatment of nasolacrimal duct obstruction with probing in children younger than 4 years.

Authors:  Michael X Repka; Danielle L Chandler; Roy W Beck; Eric R Crouch; Sean Donahue; Jonathan M Holmes; Katherine Lee; Michele Melia; Graham E Quinn; Nick A Sala; Susan Schloff; David I Silbert; David K Wallace
Journal:  Ophthalmology       Date:  2007-11-08       Impact factor: 12.079

5.  Timing of initial probing and irrigation in congenital nasolacrimal duct obstruction.

Authors:  J A Katowitz; M G Welsh
Journal:  Ophthalmology       Date:  1987-06       Impact factor: 12.079

6.  Balloon catheter dilation and nasolacrimal duct intubation for treatment of nasolacrimal duct obstruction after failed probing.

Authors:  Michael X Repka; Danielle L Chandler; Jonathan M Holmes; Darren L Hoover; Christine L Morse; Susan Schloff; David I Silbert; D Robbins Tien
Journal:  Arch Ophthalmol       Date:  2009-05
  6 in total
  6 in total

1.  [Increased prevalence of congenital dacryostenosis following cesarean section].

Authors:  Claudia Kuhli-Hattenbach; M Lüchtenberg; C Hofmann; T Kohnen
Journal:  Ophthalmologe       Date:  2016-08       Impact factor: 1.059

2.  Cost-effectiveness of 2 approaches to managing nasolacrimal duct obstruction in infants: the importance of the spontaneous resolution rate.

Authors:  Kevin D Frick; Luxme Hariharan; Michael X Repka; Danielle Chandler; B Michele Melia; Roy W Beck
Journal:  Arch Ophthalmol       Date:  2011-05

3.  Nasal endoscopic features and outcomes of nasal endoscopy guided bicanalicular intubation for complex persistent congenital nasolacrimal duct obstructions.

Authors:  Manpreet Singh; Manjula Sharma; Manpreet Kaur; Aditi Mehta Grewal; Deepti Yadav; Sabia Handa; Sonam Yangzes; Zoramthara Zadeng; Pankaj Gupta
Journal:  Indian J Ophthalmol       Date:  2019-07       Impact factor: 1.848

4.  Lacrimal surgery: Glorious past, exciting present era and the audacity of hope for a brilliant future.

Authors:  Mohammad Javed Ali
Journal:  Saudi J Ophthalmol       Date:  2013-12-17

5.  Pushed monocanalicular intubation versus probing as a primary management for congenital nasolacrimal obstruction.

Authors:  Emad Abdelaal Elsawaby; Rania Assem El Essawy; Sameh Hassan Abdelbaky; Yomna Magdy Ismail
Journal:  Clin Ophthalmol       Date:  2016-09-07

Review 6.  Congenital Nasolacrimal Duct Obstruction (CNLDO): A Review.

Authors:  Aldo Vagge; Lorenzo Ferro Desideri; Paolo Nucci; Massimiliano Serafino; Giuseppe Giannaccare; Andrea Lembo; Carlo Enrico Traverso
Journal:  Diseases       Date:  2018-10-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.